<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960815</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01540</org_study_id>
    <nct_id>NCT02960815</nct_id>
  </id_info>
  <brief_title>Imiquimod and Influenza Vaccine for Immunocompromised Patients</brief_title>
  <acronym>IMIFLU</acronym>
  <official_title>Safety and Immunogenicity of Seasonal Influenza Vaccine With Topical Imiquimod in Immunocompromised Patients: A Randomized Controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lausanne Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this open label, single centre, pilot randomized controlled clinical trial the
      investigators aim to compare the immunogenicity and safety of a new influenza vaccination
      strategy consisting in the topical administration of imiquimod at the injection site before
      vaccination vs. a standard intramuscular vaccine injection in SOT recipients and HIV-infected
      individuals. The investigators planned to enroll 70 outpatients patients (50% solid-organ
      transplant recipients and 50% HIV-infected patients) regularly followed at the
      Transplantation center and the Infectious disease outpatients' clinics of the Lausanne
      University Hospital. Study participants will be randomized in a 1:1:1 ratio to receive the
      standard intramuscular vaccine (control group) or a topical application of an imiquimod
      containing cream followed by intramuscular (imiquimod-IM) or intradermal (imiquimod-ID)
      vaccine injection. After vaccination participants will be followed for a period of 180 days.
      Blood samples will be drawn at baseline and at day 21 and 180 for assessment of
      immunogenicity. Safety outcomes will be assessed immediately after vaccine administration,
      and at day 7 (phone call), 21 and 180.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to the vaccine</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>Vaccine response rate (=seroconversion rate) at day 21 is the proportion of participants exhibiting a fourfold or greater increase of anti haemagglutinin (anti-HA) antibodies from baseline, measured by haemagglutinin inhibition (HI) assay 21 days after vaccination, for at least one viral strain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rates</measure>
    <time_frame>Baseline, 21 and 180 days after vaccination</time_frame>
    <description>Seroprotection rates for each vaccine strain at baseline, and 21 and 180 days after vaccination. Seroprotection rate is defined as the proportion of patients exhibiting an anti-HA antibody titer of 1:32 or greater.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Influenza Vaccine</condition>
  <arm_group>
    <arm_group_label>Intramuscular vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control intervention consists in the administration of the standard intramuscular influenza vaccine (Mutagrip®), containing 15 μg of each of the three viral strains without imiquimod.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imiquimod and intradermal vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the imiquimod and intradermal vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intradermal influenza vaccine preparations containing 15 μg of each of the three viral strains (Intanza®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imiquimod and intramuscular vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the imiquimod and intramuscular vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intramuscular influenza vaccine preparations containing 15 μg of each of the three viral strains (Mutagrip®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intanza</intervention_name>
    <arm_group_label>Imiquimod and intradermal vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mutagrip</intervention_name>
    <arm_group_label>Intramuscular vaccine</arm_group_label>
    <arm_group_label>Imiquimod and intramuscular vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldara</intervention_name>
    <arm_group_label>Imiquimod and intradermal vaccine</arm_group_label>
    <arm_group_label>Imiquimod and intramuscular vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written, informed consent

          -  Age &gt; 18 years

          -  HIV infection or at least 3 months after kidney transplantation

          -  Stable outpatients

          -  Able and willing to comply with the study protocol

        Exclusion Criteria:

          -  Documented egg and/or imiquimod allergy

          -  Previous life-threatening reaction to seasonal influenza vaccine (i.e. Guillain-Barré
             Syndrome)

          -  Previous severe reaction to imiquimod cream

          -  Pregnancy or breast-feeding

          -  Patients with autoimmune diseases

          -  For HIV-infected patients:

               -  Current active opportunistic infection

          -  For kidney transplant recipients:

               -  Ongoing therapy for rejection (including steroid pulse or prednisone &gt; 2
                  mg/kg/day over more than 14 days)

               -  Ongoing therapy with IVIG and eculizumab or current and past (&lt;6months) therapy
                  with rituximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oriol Manuel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D, Ellefsen K, Bart PA, Venetz JP, Calandra T, Cavassini M. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011 Jan 15;52(2):248-56. doi: 10.1093/cid/ciq104.</citation>
    <PMID>21288852</PMID>
  </results_reference>
  <results_reference>
    <citation>Cordero E, Manuel O. Influenza vaccination in solid-organ transplant recipients. Curr Opin Organ Transplant. 2012 Dec;17(6):601-8. doi: 10.1097/MOT.0b013e3283592622. Review.</citation>
    <PMID>23042206</PMID>
  </results_reference>
  <results_reference>
    <citation>Manuel O, Humar A, Berutto C, Ely L, Giulieri S, Lien D, Meylan PR, Weinkauf J, Pascual M, Nador R, Aubert JD, Kumar D. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J Heart Lung Transplant. 2011 Jun;30(6):679-84. doi: 10.1016/j.healun.2011.01.705. Epub 2011 Mar 5.</citation>
    <PMID>21377898</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne Hospitals</investigator_affiliation>
    <investigator_full_name>Oriol Manuel</investigator_full_name>
    <investigator_title>PD Dr</investigator_title>
  </responsible_party>
  <keyword>influenza vaccine</keyword>
  <keyword>Transplantation</keyword>
  <keyword>imiquimod</keyword>
  <keyword>HIV infection</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

